Pieris Pharmaceuticals

PIRS65

$16.77arrow_drop_up5.27%$0.84

PIRS65

$16.77

arrow_drop_up5.27%$0.84

Performance History

Key Stats
Open	$15.89
Prev. Close	$15.93
EPS	-12.11
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$22.14M
PE Ratio	-

	LOW	HIGH
Day Range	15.35	17.00
52 Week Range	6.20	26.80

Ratios

Revenue	-





EPS	-12.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals Inc (PIRS) is a biotechnology company that focuses on the discovery and development of innovative therapeutics. The company's main area of expertise is the development of Anticalin proteins, which are a class of small proteins designed to address a wide range of diseases. Anticalin proteins have several advantages over traditional antibodies, including higher stability, improved tissue penetration, and the ability to inhibit multiple targets simultaneously. Pieris Pharmaceuticals has a diverse pipeline of Anticalin-based drug candidates, targeting various indications such as cancer, respiratory diseases, and rare orphan diseases.

One of the key factors driving investor interest in Pieris Pharmaceuticals is its unique platform technology that enables the rapid discovery of novel Anticalin proteins. The company has established strategic collaborations with several pharmaceutical companies, including AstraZeneca, Servier, and Seattle Genetics, to advance its drug candidates through clinical development. These partnerships provide Pieris Pharmaceuticals with access to additional resources and expertise, while also validating the potential of its Anticalin platform.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Stephen S. Yoder J.D.
Headquarters: Boston
Employees: 127
Exchange: NASDAQ

Keep an eye on Pieris Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Pieris Pharmaceuticals 's (PIRS) price per share?

The current price per share for Pieris Pharmaceuticals (PIRS) is $16.77. The stock has seen a price change of $0.84 recently, indicating a 5.28% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Pieris Pharmaceuticals (PIRS)?

For Pieris Pharmaceuticals (PIRS), the 52-week high is $26.8, which is 59.76% from the current price. The 52-week low is $6.2, the current price is 170.56% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Pieris Pharmaceuticals (PIRS) a growth stock?

Pieris Pharmaceuticals (PIRS) has shown an average price growth of -4.13% over the past three years. It has received a score of 100 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pieris Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Pieris Pharmaceuticals (PIRS) stock price performance year to date (YTD)?

As of the latest data, Pieris Pharmaceuticals (PIRS) has a year-to-date price change of 12.61%. Over the past month, the stock has experienced a price change of -1.03%. Over the last three months, the change has been -7.17%. Over the past six months, the figure is 59.91%. Looking at a longer horizon, the five-year price change stands at -94.72%.

help

Is Pieris Pharmaceuticals (PIRS) a profitable company?

Pieris Pharmaceuticals (PIRS) has a net income of -$24.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 2.36% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -56.9% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 65.28%, providing insight into the company's sales performance and growth. The gross profit is $1.01M. Operating income is noted at -$29.76M. Furthermore, the EBITDA is -$11.34M.

help

What is the market capitalization of Pieris Pharmaceuticals (PIRS)?

Pieris Pharmaceuticals (PIRS) has a market capitalization of $22.15M. The average daily trading volume is 16.61, indicating the stock's liquidity and investor engagement.